Loading...
•
Jun 30, 2021
Enliven Therapeutics Q2 2021 Earnings Report
Reported financial results for the second quarter ending June 30, 2021, and reviewed recent business highlights.
Key Takeaways
Imara Inc. reported its second-quarter financial results, highlighting accelerated enrollment in Phase 2b trials for sickle cell disease and beta-thalassemia. The company also presented positive IMR-687 data and is developing a Phase 2 proof-of-concept study for HFpEF. A $50 million follow-on offering extends their cash runway through 2022.
Accelerated enrollment in Phase 2b trials in sickle cell disease and beta-thalassemia; interim analyses expected in fourth quarter of 2021.
Positive IMR-687 data in sickle cell disease presented at the European Hematology Association (EHA) Annual Congress.
HFpEF Phase 2 proof-of-concept study under development; FDA interaction planned in fourth quarter of 2021.
Closed $50 million July follow-on offering extends cash runway through 2022.
Enliven Therapeutics
Enliven Therapeutics
Forward Guidance
Imara provided financial guidance for the full year 2021 and expects its current cash resources to fund operations through the end of 2022.